IL-4 / IL-13 inhibitors
Immunology· 3 reviewed drugs· 5881 cited findings behind them
What the regulatory reviews cover
The IL-4 / IL-13 inhibitors reviewed in this library include Dupixent, Nemluvio, and Ebglyss. Dupixent has been reviewed for indications such as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP), and the treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (EoE). Nemluvio and Ebglyss were reviewed for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy, with Ebglyss specifically for adults and adolescents.
Regulatory reviews for these drugs report various outcomes. For Dupixent, an EASI-75 improvement of 76.1 was noted. Nemluvio showed an IGA success (proportion) of 35.6. Ebglyss demonstrated an IGA 0,1 with ≥2-Point reduction of 43.1, compared to 12.7 for placebo. It is important to note that these figures are derived from different trials and are not directly comparable head-to-head.
The drugs — one cited result each
| Dupixent Regeneron Pharmaceuticals, Inc. | EASI-75 improvement: 76.1 REGENERON PHARMACEUTICALS — Dupixent FDA Review (NDA/BLA 761, p.79 |
| Nemluvio Galderma | IGA success (proportion): 35.6 Galderma — Nemluvio EMA EPAR public assessment report (EMEA/, p.109 |
| Ebglyss Almirall S A | IGA 0,1 with ≥2-Point reduction: 43.1 Almirall S A — Ebglyss EMA EPAR public assessment report (EM, p.88 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Immunology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.